Chester E. Markwalter

Chester E. Markwalter

Auto-generated profile, based on publicly available information

Chester E. Markwalter

Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey 08544, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2019 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JFJie Feng
Jie Feng
CMChester E. Markwalter
Chester E. Markwalter
CTChang Tian
Chang Tian
MAMadeleine Armstrong
Madeleine Armstrong
RPRobert K. Prud'homme
Robert K. Prud'homme
“Nanomedicine” is the application of purposely designed nano-scale materials for improved therapeutic and diagnostic outcomes, which cannot be otherwise achieved using conventional delivery approaches. While “translation” in drug development commonly encompasses the steps from discovery to human clinical trials, a different set of translational steps is required in nanomedicine. Although significant development effort has been focused on nanomedicine, the translation from laboratory formulations up to large scale production has been one of the major challenges to the success of such nano-therapeutics. In particular, scale-up significantly alters momentum and mass transfer rates, which leads to different regimes for the formation of nanomedicines. Therefore, unlike the conventional definition of translational medicine, a key component of “bench-to-bedside” translational research in nanomedicine is the scale-up of the synthesis and processing of the nano-formulation to achieve precise control of the nanoscale properties. This consistency requires reproducibility of size, polydispersity and drug efficacy. Here we demonstrate that Flash NanoPrecipitation (FNP) offers a scalable and continuous technique to scale up the production rate of nanoparticles from a laboratory scale to a pilot scale. FNP is a continuous, stabilizer-directed rapid precipitation process. Lumefantrine, an anti-malaria drug, was chosen as a representative drug that was processed into 200 nm nanoparticles with enhanced bioavailability and dissolution kinetics. Three scales of mixers, including a small-scale confined impinging jet mixer, a mid-scale multi-inlet vortex mixer (MIVM) and a large-scale multi-inlet vortex mixer, were utilized in the formulation. The production rate of nanoparticles was varied from a few milligrams in a laboratory batch mode to around 1 kg/day in a continuous large-scale mode, with the size and polydispersity similar at all scales. Nanoparticles of 200 nm were made at all three scales of mixers by operating at equivalent Reynolds numbers (dynamic similarity) in each mixer. Powder X-ray diffraction and differential scanning calorimetry demonstrated that the drugs were encapsulated in an amorphous form across all production rates. Next, scalable and continuous spray drying was applied to obtain dried powders for long-term storage stability. For dissolution kinetics, spray dried samples produced by the large-scale MIVM showed 100% release in less than 2 h in both fasted and fed state intestinal fluids, similar to small-batch low-temperature lyophilization. These results validate the successful translation of a nanoparticle formulation from the discovery scale to the clinical scale. Coupling nanoparticle production using FNP processing with spray drying offers a continuous nanofabrication platform to scale up nanoparticle synthesis and processing into solid dosage forms.

1 September 2018 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
CMChester E. Markwalter
Chester E. Markwalter
RPRobert K. Prud'homme
Robert K. Prud'homme
Flash NanoPrecipitation is a scalable approach to generate polymeric nanoparticles using rapid micromixing in specially designed geometries such as a confined impinging jets mixer or a Multi-Inlet Vortex Mixer (MIVM). A major limitation of formulation screening using the MIVM is that a single run requires tens of milligrams of the therapeutic. To overcome this, we have developed a scaled-down version of the MIVM, requiring as little as 0.2 mg of therapeutic, for formulation screening. The redesigned mixer can then be attached to pumps for scale-up of the identified formulation. It was shown that Reynolds number allowed accurate scaling between the 2 MIVM designs. The utility of the small-scale MIVM for formulation development was demonstrated through the encapsulation of a number of hydrophilic macromolecules using inverse Flash NanoPrecipitation with target loadings as high as 50% by mass.

7 January 2019 in Journal of Visualized Experiments
Verified
Journal Article
Open access
PDF file
CMChester E. Markwalter
Chester E. Markwalter
RPRobert F. Pagels
Robert F. Pagels
BWBrian K. Wilson
Brian K. Wilson
Kurt RistrophKurt Ristroph
Kurt Ristroph
RPRobert K. Prud'homme
Robert K. Prud'homme
The formulation of a therapeutic compound into nanoparticles (NPs) can impart unique properties. For poorly water-soluble drugs, NP formulations can improve bioavailability and modify drug distribution within the body. For hydrophilic drugs like peptides or proteins, encapsulation within NPs can also provide protection from natural clearance mechanisms. There are few techniques for the production of polymeric NPs that are scalable. Flash NanoPrecipitation (FNP) is a process that uses engineered mixing geometries to produce NPs with narrow size distributions and tunable sizes between 30 and 400 nm. This protocol provides instructions on the laboratory-scale production of core-shell polymeric nanoparticles of a target size using FNP. The protocol can be implemented to encapsulate either hydrophilic or hydrophobic compounds with only minor modifications. The technique can be readily employed in the laboratory at milligram scale to screen formulations. Lead hits can directly be scaled up to gram- and kilogram-scale. As a continuous process, scale-up involves longer mixing process run time rather than translation to new process vessels. NPs produced by FNP are highly loaded with therapeutic, feature a dense stabilizing polymer brush, and have a size reproducibility of ± 6%.

2 January 2020 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
CMChester E. Markwalter
Chester E. Markwalter
RPRobert F. Pagels
Robert F. Pagels
AHAva N. Hejazi
Ava N. Hejazi
AGAkiva G. R. Gordon
Akiva G. R. Gordon
ATAlexandra L. Thompson
Alexandra L. Thompson
RPRobert K. Prud'homme
Robert K. Prud'homme

2 November 2018 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
RFRichard J. Fox
Richard J. Fox
NCNicolas Lucien Cuniere
Nicolas Lucien Cuniere
LBLopa Bakrania
Lopa Bakrania
CWCarolyn Wei
Carolyn Wei
NSNeil A. Strotman
Neil A. Strotman
MEMartin D. Eastgate
Martin D. Eastgate

18 October 2018 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
NSNeil A. Strotman
Neil A. Strotman
MSMaxime C. Soumeillant
Maxime C. Soumeillant
KZKeming Zhu
Keming Zhu
CMChester E. Markwalter
Chester E. Markwalter
CWCarolyn S. Wei
Carolyn S. Wei
MEMartin D. Eastgate
Martin D. Eastgate